Informed Consent for Compounded Peptides: What You Need to Document

Informed consent is your first line of defense against liability when prescribing compounded peptide therapies. Many physicians unknowingly expose themselves to risk by using generic consent forms that don't address the unique regulatory status of compounded medications.

Why Informed Consent Matters for Compounded Medications

Compounded peptides occupy a unique regulatory space. Unlike FDA-approved drugs, they haven't undergone the same rigorous approval process. This creates both opportunity and risk for providers.

When you prescribe a compounded peptide, you're prescribing a medication that:

• Has not been evaluated by the FDA for safety or efficacy
• May be used off-label for indications without clinical trial data
• Comes from a compounding pharmacy with varying quality standards
• May have inconsistent potency or purity compared to pharmaceutical-grade alternatives

Your informed consent documentation needs to make this crystal clear. If a patient experiences an adverse event and your consent form looks like it was copied from a standard pharmaceutical prescription, you've created a documentation gap that plaintiff attorneys love to exploit.

The purpose of informed consent in this context is twofold: ensuring your patient genuinely understands what they're agreeing to, and creating a legal record that demonstrates you fulfilled your duty to inform.

Legal Requirements by State

There's no federal standard for informed consent documentation—it varies significantly by state. Some states have specific requirements for compounded medications, while others rely on general informed consent statutes.

States with specific compounding consent requirements often mandate that you disclose:

• That the medication is compounded and not FDA-approved
• The name and contact information of the compounding pharmacy
• Whether a commercially available FDA-approved alternative exists

Witness signature requirements vary widely. Some states require:

• A healthcare provider witness for certain high-risk therapies
• A non-medical witness for procedures involving sedation
• No witness requirement at all

Language and readability standards are another consideration. California, for example, requires consent forms to be written at an eighth-grade reading level. New York requires translation services for non-English-speaking patients.

The practical challenge: if you serve patients across multiple states (common with telehealth), you need state-specific consent forms. A one-size-fits-all approach creates compliance gaps.

What to Include in a Peptide Therapy Consent Form

A comprehensive informed consent form for compounded peptide therapy should include these essential elements:

The language should be specific to the peptide you're prescribing. A consent form for semaglutide should look different from one for BPC-157, which should look different from one for sermorelin.

Avoid medical jargon where possible. If you must use technical terms, provide plain-language explanations. Remember: the standard isn't whether you disclosed the information, but whether a reasonable patient would have understood it.

Common Mistakes That Create Liability Exposure

Here are the most frequent informed consent mistakes I see physicians make with compounded peptide therapy:

1. Using generic pharmaceutical consent forms

Your consent form template for FDA-approved medications won't suffice. It doesn't address the unique regulatory status of compounded drugs, the lack of FDA oversight, or the potential for quality variation between compounding pharmacies.

2. No mention of compounding status

Some physicians list the peptide name without explicitly stating it's compounded. This creates the impression the patient is receiving an FDA-approved medication. If questioned later, the patient can credibly claim they didn't understand they were receiving a non-approved drug.

3. Outdated forms that don't reflect current regulations

Regulatory guidance on compounding changes regularly. A consent form created in 2023 may not reflect FDA guidance issued in 2024 or state legislation passed in 2025. Using outdated forms suggests you're not staying current with compliance requirements.

4. No documentation of verbal discussion

The consent form is just one part of informed consent. The process requires a meaningful conversation where you explain risks and benefits and answer patient questions. Many physicians fail to document this discussion in the medical record.

Best practice: Add a progress note that reads something like: "Discussed risks and benefits of compounded semaglutide including lack of FDA approval, potential for inconsistent dosing, and monitoring requirements. Patient verbalized understanding and all questions were answered to satisfaction. Written informed consent obtained and filed."

5. Failing to update consent when treatment changes

If you adjust the peptide, change the dosage significantly, or add combination therapy, you need updated consent. The original form doesn't cover the modified treatment plan.

Keeping Consent Forms Current as Regulations Change

The regulatory landscape for compounded medications is evolving rapidly. The FDA's 2024 guidance on office-use compounding, ongoing state legislation, and increased scrutiny following safety incidents all impact what you need to disclose.

Staying current requires a systematic approach:

• Quarterly review schedule: Set a recurring calendar reminder to review your consent forms every three months
• Monitor FDA communications: Subscribe to FDA alerts on compounding and peptide regulations
• Track state legislation: If you practice in multiple states, monitor each state's board of medicine and pharmacy for new requirements
• Version control: Date and version your consent forms so you can prove which version was in use at the time of patient enrollment
• Legal review: Have healthcare counsel review your forms annually or when significant regulatory changes occur

The challenge: this creates significant administrative burden, especially for solo practitioners or small practices without dedicated compliance staff.

Automated, State-Specific Consent Forms

Conviction automatically generates state-specific informed consent forms for every peptide prescription. The system:

• Pulls the correct template based on patient state of residence
• Pre-populates peptide-specific risks, benefits, and alternatives
• Includes current FDA guidance and state requirements
• Updates automatically when regulations change
• Stores signed forms with the patient chart for easy retrieval

Instead of spending hours researching state requirements and drafting custom forms for each peptide, you get compliant documentation automatically. When the FDA issues new guidance or a state changes its requirements, your forms update without manual intervention.

Informed consent is an ongoing dialogue with your patients about the unique considerations of compounded peptide therapy. The documentation should reflect that process while protecting you from liability exposure.